Cargando…
Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study
BACKGROUND: ReLiAM, Real-Life Assessment of Abilify Maintena, was the first reported long-term prospective non-interventional study for patients with schizophrenia treated with aripiprazole once-monthly injectable formulation (AOM) under real-life conditions. ReLiAM’s primary aim was to evaluate the...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733174/ https://www.ncbi.nlm.nih.gov/pubmed/36482352 http://dx.doi.org/10.1186/s12888-022-04397-x |
_version_ | 1784846306468954112 |
---|---|
author | Margolese, Howard C. Boucher, Matthieu Therrien, Francois Clerzius, Guerline |
author_facet | Margolese, Howard C. Boucher, Matthieu Therrien, Francois Clerzius, Guerline |
author_sort | Margolese, Howard C. |
collection | PubMed |
description | BACKGROUND: ReLiAM, Real-Life Assessment of Abilify Maintena, was the first reported long-term prospective non-interventional study for patients with schizophrenia treated with aripiprazole once-monthly injectable formulation (AOM) under real-life conditions. ReLiAM’s primary aim was to evaluate the evolution of global functional status in patients treated with AOM for 12 months in Canada. METHODS: The objective of this post hoc analysis of the ReLiAM study is to investigate the treatment effects of real-life use of AOM over a 1-year period in the subgroup of patients with reported substance use compared with patients without substance use. RESULTS: The results of this post hoc analysis demonstrate that treatment with AOM for 12 months in patients with schizophrenia was comparably effective in improving global functioning in subgroups of patients with and without concomitant substance use. CONCLUSIONS: These results support the use of AOM for the treatment of schizophrenia in patients with or without concomitant substance use. TRIAL REGISTRATION: ClinicalTrials.gov NCT02131415, first posted on May 6, 2014. Overall trial status: Terminated. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12888-022-04397-x. |
format | Online Article Text |
id | pubmed-9733174 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97331742022-12-10 Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study Margolese, Howard C. Boucher, Matthieu Therrien, Francois Clerzius, Guerline BMC Psychiatry Research Article BACKGROUND: ReLiAM, Real-Life Assessment of Abilify Maintena, was the first reported long-term prospective non-interventional study for patients with schizophrenia treated with aripiprazole once-monthly injectable formulation (AOM) under real-life conditions. ReLiAM’s primary aim was to evaluate the evolution of global functional status in patients treated with AOM for 12 months in Canada. METHODS: The objective of this post hoc analysis of the ReLiAM study is to investigate the treatment effects of real-life use of AOM over a 1-year period in the subgroup of patients with reported substance use compared with patients without substance use. RESULTS: The results of this post hoc analysis demonstrate that treatment with AOM for 12 months in patients with schizophrenia was comparably effective in improving global functioning in subgroups of patients with and without concomitant substance use. CONCLUSIONS: These results support the use of AOM for the treatment of schizophrenia in patients with or without concomitant substance use. TRIAL REGISTRATION: ClinicalTrials.gov NCT02131415, first posted on May 6, 2014. Overall trial status: Terminated. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12888-022-04397-x. BioMed Central 2022-12-08 /pmc/articles/PMC9733174/ /pubmed/36482352 http://dx.doi.org/10.1186/s12888-022-04397-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Margolese, Howard C. Boucher, Matthieu Therrien, Francois Clerzius, Guerline Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study |
title | Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study |
title_full | Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study |
title_fullStr | Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study |
title_full_unstemmed | Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study |
title_short | Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study |
title_sort | treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the reliam study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733174/ https://www.ncbi.nlm.nih.gov/pubmed/36482352 http://dx.doi.org/10.1186/s12888-022-04397-x |
work_keys_str_mv | AT margolesehowardc treatmentwitharipiprazoleoncemonthlyinjectableformulationiseffectiveinimprovingsymptomsandglobalfunctioninginschizophreniawithandwithoutcomorbidsubstanceuseaposthocanalysisofthereliamstudy AT bouchermatthieu treatmentwitharipiprazoleoncemonthlyinjectableformulationiseffectiveinimprovingsymptomsandglobalfunctioninginschizophreniawithandwithoutcomorbidsubstanceuseaposthocanalysisofthereliamstudy AT therrienfrancois treatmentwitharipiprazoleoncemonthlyinjectableformulationiseffectiveinimprovingsymptomsandglobalfunctioninginschizophreniawithandwithoutcomorbidsubstanceuseaposthocanalysisofthereliamstudy AT clerziusguerline treatmentwitharipiprazoleoncemonthlyinjectableformulationiseffectiveinimprovingsymptomsandglobalfunctioninginschizophreniawithandwithoutcomorbidsubstanceuseaposthocanalysisofthereliamstudy |